Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

OBJECTIVES: Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. DESIGN: This study aimed to evaluate the reduction in duration of hospitalisation with adequate oxygen...

Descripción completa

Detalles Bibliográficos
Autores principales: Generali, Daniele, Bosio, Giancarlo, Malberti, Fabio, Cuzzoli, Antonio, Testa, Sophie, Romanini, Laura, Fioravanti, Antonio, Morandini, Alessandro, Pianta, Luca, Giannotti, Guglielmo, Viola, Erika Maria, Giorgi-Pierfranceschi, Matteo, Foramitti, Marina, Tira, Rosa Angela, Zangrandi, Ilaria, Chiodelli, Giulia, Machiavelli, Andrea, Cappelletti, Maria Rosa, Giossi, Alessia, De Giuli, Valeria, Costanzi, Chiara, Campana, Chiara, Bernocchi, Ottavia, Sirico, Marianna, Zoncada, Alessia, Molteni, Alfredo, Venturini, Sergio, Giudici, Fabiola, Scaltriti, Maurizio, Pan, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771302/
https://www.ncbi.nlm.nih.gov/pubmed/33385581
http://dx.doi.org/10.1016/j.ijid.2020.12.073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771302/
https://www.ncbi.nlm.nih.gov/pubmed/33385581
http://dx.doi.org/10.1016/j.ijid.2020.12.073

Ejemplares similares